Ergonomic fluorescence-guided surgery imaging platform for intraoperative assessment of blood and lymphatic vasculature

符合人体工程学的荧光引导手术成像平台,用于术中评估血液和淋巴管系统

基本信息

  • 批准号:
    10249334
  • 负责人:
  • 金额:
    $ 82.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-07-21 至 2023-08-31
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract This proposal aims to address the unmet clinical need for intraoperative assessment of blood and lymphatic vasculature to reduce the prevalence of two breast cancer-related morbidities: lymphedema and tissue necrosis. Current imaging systems are cumbersome, requiring ambient room lights to be turned off, have poor fluorescence sensitivity, or provide images that are difficult to interpret. OnLume will develop the clinical cart- based Asimov Imaging Platform to work in combination with the FDA-approved fluorescent dye, indocyanine green, that not only enables real-time image capture of small vessels with ambient lights on without degradation to image contrast, but also is easy for surgeons to use and interpret resulting in a platform that will be optimized to provide clinical value across multiple procedures in the breast cancer surgery workflow. More than 250,000 women a year undergo surgery for breast cancer in the United States. Conventionally, surgeons rely on white light reflectance as a guide to assessing vessel patency, which is extremely difficult to visualize. Lymphedema, an incurable disease associated with damage to lymphatic vessels, may occur in up to 40% of breast cancer survivors; associated symptoms include pain, heaviness and limitations in motility and associated costs range from $3000 to $16,000 per annum. Resection of lymph nodes that drain from the breast while sparing the lymphatic channels may decrease the risk of lymphedema. Some women who undergo mastectomy may choose breast reconstruction with a free flap surgery, where plastic surgeons reattach blood vessels between donor and recipient tissue sites to reconstruct a breast mound. Surgeons must assess vessel patency to decrease the risk of tissue necrosis and secondary operations. In 15-25% of cases, patients undergo secondary surgery to correct tissue necrosis, incurring costs that can exceed $14,000 per procedure. Our novel imaging system will be evaluated in a pilot study to measure the efficacy of the visualization of the blood and lymphatic architecture. This Phase II proposal has three specific aims: (1) complete development and integration of novel technology into a clinical transient lighting-enabled, wide-field fluorescence-guided surgery cart-based imaging platform, (2) demonstrate enhanced contrast of lymphatics for axillary reverse mapping (ARM), and (3) evaluate blood vessel patency in free flap breast reconstruction. Successful completion will result in a commercially available clinical wide-field FGS imaging system, providing critical intraoperative imaging that could enable breast surgeons and plastic surgeons to improve the health and quality of life for breast cancer survivors.
项目概要/摘要 该提案旨在解决术中评估血液和淋巴管的未满足的临床需求 脉管系统可降低两种乳腺癌相关疾病的患病率:淋巴水肿和组织 坏死。目前的成像系统很笨重,需要关闭房间周围的灯光,成像效果差 荧光敏感性,或提供难以解释的图像。 OnLume 将开发临床车- 基于 Asimov 成像平台,可与 FDA 批准的荧光染料吲哚菁结合使用 绿色,不仅可以在环境灯打开的情况下实时捕获小型船只的图像,而无需 图像对比度下降,但也易于外科医生使用和解释,从而形成一个平台 进行优化,以在乳腺癌手术工作流程中的多个程序中提供临床价值。 在美国,每年有超过 250,000 名女性接受乳腺癌手术。按照惯例, 外科医生依靠白光反射率作为评估血管通畅性的指南,但这是极其困难的 可视化。淋巴水肿是一种与淋巴管损伤相关的不治之症,可能发生在 40% 的乳腺癌幸存者;相关症状包括疼痛、沉重和活动受限 相关费用每年从 3000 美元到 16,000 美元不等。切除从淋巴结引流的淋巴结 乳房同时保留淋巴管可能会降低淋巴水肿的风险。 一些接受乳房切除术的女性可能会选择游离皮瓣手术进行乳房重建,其中 整形外科医生在供体和受体组织部位之间重新连接血管以重建乳房 冢。外科医生必须评估血管通畅性,以降低组织坏死和继发性病变的风险 运营。在 15-25% 的病例中,患者接受二次手术以纠正组织坏死,从而产生费用 每次手术的费用可能超过 14,000 美元。 我们的新型成像系统将在一项试点研究中进行评估,以衡量可视化效果 血液和淋巴结构。第二阶段提案有三个具体目标:(1)完成开发 并将新技术集成到临床瞬态照明、宽视场荧光引导 基于手术车的成像平台,(2) 证明腋窝反转的淋巴管对比度增强 标测(ARM),(3)评估游离皮瓣乳房重建中的血管通畅性。成功的 完成后将产生商业化的临床广域 FGS 成像系统,提供关键的 术中成像可以使乳腺外科医生和整形外科医生改善健康状况 乳腺癌幸存者的生活质量。

项目成果

期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Receptor-Targeted Fluorescence-Guided Surgery With Low Molecular Weight Agents.
  • DOI:
    10.3389/fonc.2021.674083
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    4.7
  • 作者:
    Hernandez Vargas S;Lin C;Tran Cao HS;Ikoma N;AghaAmiri S;Ghosh SC;Uselmann AJ;Azhdarinia A
  • 通讯作者:
    Azhdarinia A
Lighting the Way for Necrosis Excision Through Indocyanine Green Fluorescence-Guided Surgery.
通过吲哚菁绿荧光引导手术照亮坏死切除之路。
  • DOI:
    10.1097/xcs.0000000000000329
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    5.2
  • 作者:
    Zajac,JocelynC;Liu,Aiping;Uselmann,AdamJ;Lin,Christie;Hassan,SameehaE;Faucher,LeeD;Gibson,AngelaLf
  • 通讯作者:
    Gibson,AngelaLf
A proof-of-concept methodology to validate the in situ visualization of residual disease using cancer-targeted molecular agents in fluorescence-guided surgery.
一种概念验证方法,用于验证在荧光引导手术中使用癌症靶向分子制剂对残留病灶进行原位可视化。
Augmentation of Chicken Thigh Model with Fluorescence Imaging Allows for Real-Time, High Fidelity Assessment in Supermicrosurgery Training.
使用荧光成像的鸡大腿模型的增强可以在超级外科手术训练中进行实时高保真评估。
  • DOI:
    10.1055/s-0040-1722184
  • 发表时间:
    2021-07
  • 期刊:
  • 影响因子:
    2.1
  • 作者:
    Albano, Nicholas J.;Zeng, Weifeng;Lin, Christie;Uselmann, Adam J.;Eliceiri, Kevin W.;Poore, Samuel O.
  • 通讯作者:
    Poore, Samuel O.
Evolution of ischemia and neovascularization in a murine model of full thickness human wound healing.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Adam John Uselmann其他文献

Adam John Uselmann的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Adam John Uselmann', 18)}}的其他基金

Transient Lighting for Fluorescence Image-Guided Surgery
用于荧光图像引导手术的瞬态照明
  • 批准号:
    9202254
  • 财政年份:
    2016
  • 资助金额:
    $ 82.25万
  • 项目类别:
Ergonomic fluorescence-guided surgery imaging platform for intraoperative assessment of blood and lymphatic vasculature
符合人体工程学的荧光引导手术成像平台,用于术中评估血液和淋巴管系统
  • 批准号:
    10082058
  • 财政年份:
    2016
  • 资助金额:
    $ 82.25万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 82.25万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 82.25万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 82.25万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 82.25万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 82.25万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 82.25万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 82.25万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 82.25万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 82.25万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 82.25万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了